favid + sargramostim

**favid + sargramostim** is a combination therapy composed of two separate agents: - **FAVID** (likely intended to refer to favipiravir, though "FAVID" is not a recognized international nonproprietary name or brand; verification needed—see comments). - **Sargramostim**, a yeast-derived recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), which stimulates production and activation of white blood cells, particularly neutrophils, monocytes, and macrophages. Sargramostim is used therapeutically for hematopoietic recovery following chemotherapy, bone marrow transplantation, radiation exposure, and more recently as an immune modulator in combination with immune checkpoint inhibitors in oncology (e.g., metastatic melanoma)[4][6]. There is no evidence of a clinically recognized combination or co-formulation or published trial data specifically for "favid + sargramostim." Sargramostim is, however, well characterized as an adjunct with immune checkpoint inhibitors for solid tumors, especially melanoma[1][2][4].